Alzpath: Alzpath Dx

Alzpath said this week it has launched its Alzpath Dx blood test for Alzheimer's disease. The test measures levels of phosphorylated-tau 217 using Quanterix's Simoa technology to help assess the likelihood a patient has the brain amyloid pathology characteristic of Alzheimer's disease.

The company is selling the test as a laboratory-developed test offered through lab firm Neurocode USA. The test costs between $300 and $500.